<DOC>
	<DOCNO>NCT00249132</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety different dos risperidone ( antipsychotic medication ) compare placebo fix 20 mg/day dose standard antipsychotic , haloperidol , patient chronic schizophrenia .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Compared With Haloperidol Placebo Patients With Chronic Schizophrenia</brief_title>
	<detailed_description>Chronic schizophrenia longer-term condition characterize lack drive , underactivity slowness , social withdrawal . As acute form schizophrenia , delusion hallucination common . This randomized , double-blind , parallel-group study evaluate effectiveness safety four dosage risperidone ( 2 , 6 , 10 16 mg/day ) compare placebo fix 20 mg/day dose standard antipsychotic , haloperidol patient chronic schizophrenia in-patients begin study . The study compose two phase : 1-week period , patient receive placebo current medication schizophrenia treatment stop , follow double-blind treatment phase . The dos study drug increase progressively first week double-blind period remain constant next 7 week . The primary measure effectiveness percentage patient show clinical improvement ( reduction &gt; =20 % baseline ) Positive Negative Syndrome Scale Schizophrenia ( PANSS ) total PANSS score , baseline end double-blind treatment . The PANSS rating scale measure symptoms schizophrenia . Safety evaluation include incidence adverse event , result clinical laboratory test ( hematology , biochemistry , urinalysis ) , plasma level risperidone , measurement vital sign body weight , physical examination electrocardiogram ( ECG ) finding , neurological examination , Extrapyramidal Symptoms Rating Scale ( ESRS ) , scale use measure effect antipsychotic medication motor function patient . The study hypothesis risperidone effective placebo , measure clinical improvement PANSS average total score PANSS , patient chronic schizophrenia . Risperidone tablet , take orally , start 1 mg twice daily , gradually increase dose Week 1 ( except 1 mg twice daily group ) , 1 , 3 , 5 , 8 mg twice daily , continue 7 week . Haloperidol tablet , start 1 mg twice daily increase 10 mg twice daily ( Week 1 ) , continue 10 mg twice daily 7 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients diagnosis chronic schizophrenic disorder , accord Diagnostic Statistical Manual Mental Diseases , 3rd edition ( DSMIIIR ) criterion inpatient begin study total score PANSS ( Positive Negative Syndrome Scale Schizophrenia ) rating scale study entry &gt; =60 &lt; =120 females childbearing age must demonstrate adequate birth control measure negative pregnancy test study entry . Patients mental disorder chronic schizophrenic disorder patient clinically significant organic neurological disease patient epilepsy history alcohol drug abuse history within 6 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>chronic schizophrenia</keyword>
	<keyword>psychotic disorder</keyword>
	<keyword>risperidone</keyword>
	<keyword>antipsychotic agent</keyword>
</DOC>